Corbus Pharmaceuticals (CRBP) Proxy filing summary

Executive summary

• Annual Meeting scheduled for May 13, 2026, to be held virtually, with voting on key proposals including director elections, equity plan amendment, auditor ratification, and executive compensation approval.

• Board recommends voting for all director nominees, the equity plan amendment, auditor ratification, and annual say-on-pay votes.

• Proxy materials and annual report are available online, with multiple voting methods provided for shareholder convenience.

Voting matters and shareholder proposals

• Shareholders will vote to elect six directors, approve an amendment to the 2024 Equity Compensation Plan (increasing authorized shares by 3,000,000 to 5,000,000), ratify EisnerAmper LLP as auditor, approve executive compensation, and determine the frequency of future say-on-pay votes.

• Board recommends annual say-on-pay votes and supports all proposals.

• Shareholder proposals for the 2027 meeting must be submitted by December 3, 2026.

Board of directors and corporate governance

• Board consists of six directors, with a majority deemed independent under Nasdaq rules.

• Board committees include Audit, Compensation, and Nominating & Corporate Governance, all with independent members.

• Board met five times in 2025; all directors attended at least 75% of meetings.

• Leadership structure separates CEO and Chair roles to enhance oversight.

• Code of Business Conduct and Ethics, insider trading, and anti-hedging policies are in place.